Savas Theodore Tsikis, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Short Bowel Syndrome | 6 | 2024 | 353 | 3.420 |
Why?
|
Antithrombins | 2 | 2023 | 294 | 1.420 |
Why?
|
Heparin | 5 | 2024 | 1634 | 1.220 |
Why?
|
Parenteral Nutrition | 7 | 2024 | 659 | 0.940 |
Why?
|
Pipecolic Acids | 1 | 2023 | 77 | 0.870 |
Why?
|
Intestinal Diseases | 5 | 2024 | 504 | 0.760 |
Why?
|
Papillomaviridae | 2 | 2018 | 1119 | 0.760 |
Why?
|
Choledocholithiasis | 1 | 2021 | 49 | 0.750 |
Why?
|
Intestinal Neoplasms | 1 | 2023 | 312 | 0.710 |
Why?
|
Arginine | 1 | 2023 | 934 | 0.690 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2021 | 232 | 0.670 |
Why?
|
Intestine, Small | 2 | 2023 | 1206 | 0.650 |
Why?
|
Acute Lung Injury | 1 | 2022 | 367 | 0.620 |
Why?
|
Surgery Department, Hospital | 1 | 2019 | 176 | 0.590 |
Why?
|
Papillomavirus Infections | 3 | 2018 | 1613 | 0.570 |
Why?
|
Liver Failure | 3 | 2024 | 250 | 0.560 |
Why?
|
Hypertension, Pulmonary | 2 | 2023 | 1578 | 0.510 |
Why?
|
Penile Neoplasms | 1 | 2016 | 161 | 0.490 |
Why?
|
Swine | 7 | 2024 | 5915 | 0.490 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2206 | 0.470 |
Why?
|
Hospitals, Teaching | 1 | 2019 | 1156 | 0.460 |
Why?
|
Liver Diseases | 4 | 2024 | 1298 | 0.450 |
Why?
|
Erectile Dysfunction | 1 | 2017 | 444 | 0.450 |
Why?
|
Sulfonamides | 1 | 2023 | 1978 | 0.450 |
Why?
|
Urinary Incontinence | 1 | 2017 | 489 | 0.430 |
Why?
|
Program Development | 1 | 2019 | 1297 | 0.420 |
Why?
|
Anus Neoplasms | 1 | 2016 | 329 | 0.420 |
Why?
|
Enteral Nutrition | 3 | 2023 | 794 | 0.400 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2016 | 491 | 0.360 |
Why?
|
Catheter-Related Infections | 2 | 2024 | 273 | 0.360 |
Why?
|
Cholestasis | 2 | 2023 | 378 | 0.340 |
Why?
|
Prostatectomy | 1 | 2017 | 1824 | 0.330 |
Why?
|
Soybean Oil | 3 | 2024 | 139 | 0.310 |
Why?
|
Catheterization, Central Venous | 2 | 2024 | 526 | 0.310 |
Why?
|
Fat Emulsions, Intravenous | 4 | 2024 | 314 | 0.310 |
Why?
|
Pneumonectomy | 2 | 2023 | 1119 | 0.270 |
Why?
|
Intestines | 3 | 2024 | 1909 | 0.260 |
Why?
|
Lung | 5 | 2023 | 10002 | 0.250 |
Why?
|
Mice, Inbred C57BL | 4 | 2024 | 22172 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2020 | 0.230 |
Why?
|
Animals | 16 | 2024 | 168467 | 0.230 |
Why?
|
Edetic Acid | 1 | 2024 | 280 | 0.220 |
Why?
|
Disease Models, Animal | 7 | 2023 | 18253 | 0.220 |
Why?
|
Vitamins | 2 | 2022 | 1635 | 0.220 |
Why?
|
Biomedical Research | 1 | 2019 | 3429 | 0.220 |
Why?
|
Arachidonic Acid | 1 | 2024 | 427 | 0.210 |
Why?
|
Intestinal Absorption | 1 | 2024 | 400 | 0.210 |
Why?
|
Hirudins | 1 | 2023 | 179 | 0.210 |
Why?
|
Intestinal Volvulus | 1 | 2023 | 82 | 0.200 |
Why?
|
Cholangiography | 1 | 2021 | 181 | 0.190 |
Why?
|
Thrombin | 1 | 2023 | 591 | 0.190 |
Why?
|
Greece | 2 | 2018 | 340 | 0.180 |
Why?
|
Fatty Liver | 2 | 2024 | 790 | 0.180 |
Why?
|
Bile Acids and Salts | 1 | 2023 | 393 | 0.180 |
Why?
|
Nutritional Support | 1 | 2022 | 173 | 0.170 |
Why?
|
Fish Oils | 4 | 2024 | 483 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 857 | 0.160 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2021 | 506 | 0.160 |
Why?
|
Mice | 7 | 2024 | 81533 | 0.150 |
Why?
|
Anticoagulants | 3 | 2023 | 4812 | 0.150 |
Why?
|
Mammals | 1 | 2023 | 1132 | 0.150 |
Why?
|
Digestive System Surgical Procedures | 1 | 2023 | 572 | 0.150 |
Why?
|
Intraoperative Care | 1 | 2021 | 767 | 0.150 |
Why?
|
Docosahexaenoic Acids | 1 | 2024 | 908 | 0.150 |
Why?
|
Penis | 1 | 2018 | 212 | 0.140 |
Why?
|
Animals, Newborn | 1 | 2023 | 2677 | 0.140 |
Why?
|
Bacteremia | 1 | 2023 | 980 | 0.130 |
Why?
|
Efficiency | 1 | 2019 | 476 | 0.130 |
Why?
|
Mouth | 1 | 2018 | 381 | 0.130 |
Why?
|
Anal Canal | 1 | 2018 | 373 | 0.130 |
Why?
|
Energy Intake | 1 | 2023 | 2134 | 0.120 |
Why?
|
Down-Regulation | 1 | 2022 | 2919 | 0.120 |
Why?
|
Infant, Premature | 1 | 2024 | 2107 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2019 | 644 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3492 | 0.120 |
Why?
|
Liver | 3 | 2024 | 7529 | 0.110 |
Why?
|
Fibrinolytic Agents | 1 | 2023 | 2084 | 0.110 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6534 | 0.110 |
Why?
|
Nutritional Status | 1 | 2022 | 1615 | 0.110 |
Why?
|
Triage | 1 | 2020 | 986 | 0.110 |
Why?
|
Clinical Protocols | 1 | 2019 | 1440 | 0.110 |
Why?
|
Humans | 22 | 2024 | 761572 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2020 | 954 | 0.100 |
Why?
|
HIV Infections | 1 | 2018 | 17352 | 0.100 |
Why?
|
DNA, Viral | 1 | 2018 | 2202 | 0.100 |
Why?
|
Fatty Acids | 3 | 2023 | 1808 | 0.090 |
Why?
|
Infant, Newborn | 4 | 2024 | 26198 | 0.090 |
Why?
|
Papillomavirus Vaccines | 1 | 2017 | 496 | 0.090 |
Why?
|
HIV | 1 | 2018 | 1582 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2023 | 5112 | 0.090 |
Why?
|
Program Evaluation | 1 | 2019 | 2495 | 0.090 |
Why?
|
Male | 10 | 2024 | 360842 | 0.090 |
Why?
|
Hemorrhage | 1 | 2021 | 3424 | 0.080 |
Why?
|
Retrospective Studies | 6 | 2024 | 80646 | 0.070 |
Why?
|
Risk Factors | 3 | 2018 | 74213 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 3639 | 0.060 |
Why?
|
Diet | 1 | 2024 | 8075 | 0.060 |
Why?
|
Triglycerides | 2 | 2023 | 2461 | 0.060 |
Why?
|
Vaccination | 1 | 2017 | 3384 | 0.060 |
Why?
|
Prevalence | 2 | 2018 | 15732 | 0.060 |
Why?
|
Compassionate Use Trials | 1 | 2024 | 50 | 0.060 |
Why?
|
Genotype | 1 | 2018 | 12990 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3205 | 0.050 |
Why?
|
Emulsions | 1 | 2023 | 152 | 0.050 |
Why?
|
Incidence | 2 | 2022 | 21355 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4016 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2023 | 15633 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
PPAR alpha | 1 | 2023 | 175 | 0.050 |
Why?
|
Carbohydrates | 1 | 2023 | 390 | 0.050 |
Why?
|
Swine, Miniature | 1 | 2023 | 961 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 436 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 344 | 0.040 |
Why?
|
Pericytes | 1 | 2023 | 293 | 0.040 |
Why?
|
PPAR gamma | 1 | 2023 | 484 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2023 | 3548 | 0.040 |
Why?
|
Vomiting | 1 | 2023 | 651 | 0.040 |
Why?
|
Injury Severity Score | 1 | 2021 | 1045 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 26127 | 0.040 |
Why?
|
Ethanol | 1 | 2023 | 1324 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2023 | 1071 | 0.030 |
Why?
|
Infant | 3 | 2024 | 36192 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2049 | 0.030 |
Why?
|
Quality of Life | 1 | 2017 | 13367 | 0.030 |
Why?
|
Unsafe Sex | 1 | 2017 | 238 | 0.030 |
Why?
|
Middle Aged | 3 | 2018 | 220920 | 0.030 |
Why?
|
Child | 4 | 2024 | 80156 | 0.030 |
Why?
|
Young Adult | 2 | 2018 | 59255 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11122 | 0.030 |
Why?
|
Cesarean Section | 1 | 2023 | 1398 | 0.030 |
Why?
|
Female | 5 | 2024 | 392686 | 0.020 |
Why?
|
Adult | 3 | 2023 | 221203 | 0.020 |
Why?
|
Neoplasms | 1 | 2017 | 22173 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6426 | 0.020 |
Why?
|
Aged | 1 | 2017 | 169310 | 0.010 |
Why?
|
Inflammation | 1 | 2024 | 10773 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10553 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41493 | 0.010 |
Why?
|
Child, Preschool | 1 | 2024 | 42230 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 29876 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2023 | 64684 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 88324 | 0.010 |
Why?
|